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Abstract  
Objective: The objective of the selective EBM review is to determine whether or not 
Rabeprazole is a safe treatment for GERD in children less than sixteen years old. 
Study Design: Review of three randomized controlled studies. All three studies were published 
in English between 2007-2013. 
Data Sources: Three randomized, un-blinded, controlled studies found using Medline and 
PubMed 
Outcomes Measured: Each trial measured the adverse events that occurred with the use of 
Rabeprazole for the treatment of GERD in children less than sixteen years of age. This was done 
by using subjective reporting of treatment-emergent adverse events (TEAE’s). Differences in the 
frequency of Treatment Emergent Signs and Symptoms (TESS) between the two treatment 
groups analyzed using the Fischer exact test and/or an appropriate nonparametric procedure.  
Results: Three un-blinded RCT’s were included in this review and it was found that Rabeprazole 
did not lead to any significant life-threatening treatment-emergent adverse events (TEAE’s) in 
patients less than sixteen years of age. The most common adverse events were headache, 
nausea, cough, vomiting, abdominal pain, and diarrhea.   
Conclusions: Based on these three trials, Rabeprazole is a safe treatment for GERD in children 
less than sixteen years of age. Each study showed a significant improvement of symptoms 
without any serious side effects when using Rabeprazole 
Key Words: Rabeprazole, GERD, and children 
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INTRODUCTION  
 Gastroesophageal Reflux “GER” is the passage of gastric contents into the esophagus 
with or without regurgitation or vomiting.1 Physiologic “GER” is a very common and normal 
process  in infants and slightly older children, however when this process becomes chronic and 
GERD develops it can lead to more serious symptoms such as swallowing difficulties that lead to 
weight loss, failure to thrive, and respiratory problems.1 If these symptoms are not treated in 
time it can lead to long-term complications and a decreased quality of life for these children. 1 
This paper evaluates three randomized controlled trials comparing the safety of Rabeprazole 
for the treatment of children less than sixteen years old with GERD.  
 Reflux is an extremely common complaint from patients with about 18-27% of North 
America’s population being effected.6 So, because of its prevalence in this country it is relevant 
to the Physician Assistant profession. “GER” occurs in almost 100% of infants and is a normal 
process that typically resolves by the age of one.1 Although, it is thought that approximately 2-
22% of children between the ages of 3-18 years have GERD symptoms, but the exact statistics 
remain unknown.1 The annual medical cost per patient in 2006 was $6,878.6 Medical services 
which include doctor visits, hospitalizations, ER costs, and lab costs totaled to about $4,200, 
and prescription drug costs were estimated to be about $922.6   Gastrointestinal visits to the 
hospital, with GERD being the most common, represent about 8.9 million hospital visits each 
year. 4 Outpatient endoscopy’s used to diagnose GERD cost about $32.4 billion dollars each 
year.4  
 The exact cause of GERD is unknown however there are many contributing factors that 
exacerbate symptoms. These factors include smoking, alcohol, obesity, eating large meals, 
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eating too soon or right before bed, hiatal hernias, pregnancy and diabetes.5 Certain foods can 
increase GERD symptoms as well, these include chocolate, fried or fatty foods, caffeine, acidic 
foods such as fruits and tomatoes, and spicy foods.5  
 Typically the first line treatment for GERD involves lifestyle modifications.5 These 
modifications include changes such as no food within three hours of bed, no large meals, raising 
the head of the bed, weight loss, avoiding alcohol, smoking cessation.5 Also it is recommended 
that patients avoid the foods previously mentioned as they are known to increase GERD 
symptoms.5 If these lifestyle modifications do not provide adequate relief for the patient the 
next step is the use of antacids, H2 blockers, or Proton Pump Inhibitors.5 There are surgical 
options for treatment such as fundoplication, although these are usually reserved as a last 
resort.5  
While there is currently no cure for GERD, all of the lifestyle modifications and medical 
treatment options listed above have seemed to improve symptoms in adult patients with GERD. 
This topic is being proposed to address the safety of this treatment option in younger 
populations to hopefully reduce symptoms and improve their quality of life.  
OBJECTIVE  
The objective of this systematic review is to determine whether or not Rabeprazole is a safe 
treatment for GERD in children less than sixteen years of age.  
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METHODS  
Three un-blinded randomized controlled trials were used in this study. The population includes 
patients ages 1-16 years of age with a diagnosis of GERD. The intervention was the proton 
pump inhibitor Rabeprazole. All three of the studies were divided into two parts and the two 
parts were compared for TEAE’s. Throughout the first section of the Haddad and Zannikos 
studies the patients were given approximately 0.14 mg/kg of Rabeprazole which is comparable 
to the lowest effective adult dose of the medication which is 10 mg, and they were observed 
for adverse events or reactions to the medications.1,3 Then during the second part of the 
Haddad and Zannikos studies patients were randomized into two different groups and given a 
dose of Rabeprazole from the 0.5-1.0 mg/kg range.1,3 In the first part of the James study the 
patients received the lowest effective 10 mg dose of Rabeprazole and observed for adverse 
events or reactions to the medication.2Then during the second part of the James study the 
patients were randomized into two different groups and they either received another 10 mg 
dose or a higher 20 mg dose of Rabeprazole and observed for adverse events or reactions to 
the medications.2  
 Key words used to research these articles were Rabeprazole, GERD, and children. All 
three articles were researched by the author and obtained through either Medline or PubMed. 
The articles were published in English and published in peer-reviewed journals. These articles 
were chosen based on the types of studies and relevance to the clinical question. The inclusion 
criteria for this search included randomized controlled trials in which the outcomes directly 
benefited the patient population in the selected age range. Exclusion criteria included patients 
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over the age of sixteen, pregnant or lactating patients, patients with allergies to PPI’s, H. pylori 
infection, or previous acid lowering surgery or previous esophageal/gastric surgery. The 
statistics used and reported were numbers needed to treat (NNT), relative risk reduction (RRR), 
absolute risk reduction (ARR), and p-values. Table 1 displays the characteristics and 
demographics included in these studies.  
Table 1 – Demographics and Characteristic of included studies  
Study  Type  # Pts  Age 
(yrs) 
Inclusion 
criteria 
Exclusion criteria  W/D Interventions 
Haddad1 (2013) RCT 127 1-11 Pts ages 1-11 
who have 
endoscopically 
proven GERD 
-Allergies to PPI’s  
-H. Pylori infection 
19 Rabeprazole 
10 mg and 20 
mg once daily 
orally  
James2 (2007) RCT 19 12-16 Pts ages 12-16 
with a clinical 
dx of GERD 
and minimum 
body weight of 
30 kg 
-evidence of other 
significant health 
condition 
-pregnant/lactating 
females  
-unwilling to refrain 
from 
smoking/drinking 
alcohol 
-drug 
allergy/sensitivity to 
PPI’s 
-significant 
viral/bacterial 
infection within 1 
month of screening 
-definitive acid 
lowering surgery or 
previous 
esophageal/gastric 
surgery 
1 Rabeprazole 
10 mg and 20 
mg once daily 
orally  
Zannikos3 (2011) RCT 24 1-11 Pts ages 1-11 
with GERD and 
a minimum 
-history of or current 
clinically significant 
medical illness 
-H. pylori infection 
0 Rabeprazole 
0.5 mg or 1 
mg once daily 
orally  
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body weight of 
10 kg 
-sensitivity to PPI’s 
 
 
OUTCOMES MEASURED  
The outcomes measured in this study were the presence and severity of treatment-emergent 
adverse events (TEAE’s) related to the use of Rabeprazole.1,2,3 The patients involved in each of 
these studies were assessed at each study visit for TEAE’s. These assessments included physical 
examinations, vital signs, 12-lead ECG, and lab tests such as hematology, chemistry, and 
urinalysis were done.1,2,3 Most of the TEAE’s in this study were discovered through subjective 
reporting by the patients themselves.1,2,3 Differences in frequency of treatment emergent signs 
and symptoms (TESS) between the two treatment groups were analyzed using the Fischer exact 
test and/or an appropriate nonparametric procedure.2  
RESULTS 
 This review examined three RCT’s including children ages 1-16 with a known history of 
GERD and then compared the use of a low dose of Rabeprazole in the first part of each study to 
a higher dose of Rabeprazole in the second part of each study for the treatment of GERD. The 
results of all three studies was reported as dichotomous data and therefore allowed examiners 
to assess the safety of the medication and any adverse events.1,2,3  
 In the James study there were a total of twenty-four subjects that enrolled in and 
completed the study.2 Those patients with evidence of other significant health conditions, 
pregnant/lactating patients, patients unwilling to refrain from smoking or drinking alcohol 
during the study, patients with drug allergies or sensitivities to PPI’s, patients with significant 
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viral or bacterial infection within one month of the screening period, patients who have had 
definitive acid lowering surgery or previous esophageal or gastric surgery were excluded from 
the study.2  The subjects were separated into two groups based on their ages (12 - <14 years 
and 14-16 years) and then randomized to receive either a 10 mg or 20 mg dose of Rabeprazole 
during the second part of this study.2 Those subjects who fell into the 12- <14 years range were 
considered the control group and were given 10mg doses of Rabeprazole.2 Those subjects who 
fell into the 14-16 years range were considered the experimental group and were given 20mg 
doses of Rabeprazole.2   No deaths or serious adverse events (SAE’s) were reported during this 
study, and there were also no adverse events which led to patients withdrawing from the 
study.2 The incidence or CER of treatment emergent signs and symptoms in the control group 
was 50%.2  The incidence or EER of treatment emergent signs and symptoms in the 
experimental group was 41.7%.2  Headache (16.7%)  and nausea (8.3%) were the most common 
adverse events reported by subjects in this study.2 The incidence of TESS that were considered 
to be related to the study were not however, considered to be clinically significant by the 
examiners.2 The relative risk ratio (RRR) was calculated to be -16.6%.2  This means that those 
subjects in the experimental group taking the higher dose of Rabeprazole have a 16.6% higher 
risk of developing an adverse event versus those in the control group taking the lower dose. 
The absolute risk reduction (ARR) was calculated to be -8.3%.2 This means that of those taking 
in the experimental group taking the higher dose of Rabeprazole, 8.3% more will develop an 
adverse event compared to those in the control group taking the lower dose. The numbers 
needed to harm (NNH) was calculated to be -12.2 This means that for every 12 patients taking 
the higher dose of Rabeprazole, 1 fewer would experience an adverse event.   
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 In the Haddad study, patient’s ages ranged from 1-11 years of age.1 The subjects were 
divided by weight into two cohorts; a low-weight cohort (6-14.9 kg) and a high weight cohort 
(>15 kg) .1 The low weight cohort was the control group and the high weight cohort was the 
experimental group.  These patients were then randomized to receive 5-10 mg of Rabeprazole 
in the low-weight cohort and 10-20 mg of Rabeprazole in the high-weight cohort.1 Those 
patients with H. Pylori infection and allergies to PPI’s were excluded from the study.1 The 
incidence or CER of TEAE’s in the control group of this study was 77.5%.1  The incidence or EER 
of TEAE’s in the experimental group of this study was 74.7%.1  The most common reported 
TEAE’s were vomiting, cough, abdominal pain.1 There were no trends of TEAE’s or clinically 
relevant changes seen in this study.1 The relative risk ratio (RRR) was calculated to be -3.6%.1 
This means that those patients in the experimental group taking the higher doses of 
Rabeprazole have a 3.6% higher risk of developing an adverse event versus those in the control 
group. The absolute risk reduction (ARR) was calculated to be -2.8, which represents that of 
those in the experimental group taking the higher dose of Rabeprazole, 2.8% more will develop 
an adverse event compared to those in the control group taking the lower dose.  The numbers 
needed to harm(NNH) was calculated to be -35.1 This means that for every 35 patients taking 
the higher dose of Rabeprazole, 1 fewer would experience an adverse.  
 In the Zannikos study, patient’s ages ranged from 1-11 years of age.3 “Eight patients 
received 0.14 mg/kg of Rabeprazole during part one of the study.3 During part two of this study 
11 patients were randomized to receive 0.5 mg/kg of Rabeprazole and 9 patients were 
randomized to receive approximately 1 mg/kg of Rabeprazole.”3 Patients with evidence of 
other significant health conditions, with H. Pylori infection, and those patients with sensitivity 
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or allergies to PPI’s were excluded from the study.3 There were no deaths reported during this 
study.3 One patient withdrew from the study on day five; she was diagnosed with moderate 
viral gastritis on day four and developed a volvulus on day seven.3 These events were not 
considered to be related to the study.3 The incidence or CER of TEAE’s in the control group of 
this study was 81.8%.3 The incidence or EER of treatment TEAE’s in the experimental group of 
this study was 77.8%.3  “Most of the TEAE’s were mild in severity and not considered to be 
related to the study drug.”3 Vomiting (10.7%) was the most commonly reported adverse event 
reported by subjects in this study.3 There were no trends of TEAE’s or clinically relevant changes 
seen in this study.3 The relative risk ratio (RRR) was calculated to be -4.9%.3 This means that 
those in the experimental group taking the higher doses of Rabeprazole have a 4.9% higher risk 
of developing an adverse event versus those in the control group who received the lower dose. 
The absolute risk ratio (ARR) was calculated to be -4% which means that of those in the 
experimental group taking the higher dose of Rabeprazole 4% more will develop an adverse 
event compared to those in the control group who took the lower dose.3 The numbers needed 
to harm (NNH) was calculated to be -25. This means that for every 25 people taking the higher 
dose of Rabeprazole 1 fewer would experience an adverse event.  
Table 2. Treatment Effects  
STUDY P-value CER EER RRR ARR NNH 
James P = <0.001 42% 38% -9.52% -4% -25 
Haddad  P = <0.001 42% 38% -9.52% -4% -25 
Zannikos P = <0.001 81.8% 77.8% -4.9% -4% -25 
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DISCUSSION 
Rabeprazole is a proton pump inhibitor indicated for the use of duodenal ulcers, GERD, 
H. Pylori eradication, and hypersecretory conditions like Zollinger-Ellison syndrome.8 Two off 
label uses of Rabeprazole include the maintenance of healing and prevention of Duodenal 
ulcers as well as the treatment and prevention of NSAID-induced ulcers.8 The only 
contraindication to the use of Rabeprazole is if the patient has a hypersensitivity to 
Rabeprazole, substituted benzimidazoles, or any other component of the formulation.8 There 
are several warnings/precautions regarding the use of Rabeprazole. “The use of PPI’s may 
increase the risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized 
patients.”8 Because of this, it is recommended that patients use the lowest dose of the 
medication for the shortest duration appropriate for the condition being treated.8 There is 
increased risk of osteoporosis-related bone fractures with PPI therapy.8 It is recommended that 
those patients on high dose (multiple daily doses) or long-term therapy (one year or longer) 
should be monitored.8 Also, PPI’s are known to diminish the therapeutic effect of Clopidogrel 
and should be avoided in patients taking Clopidogrel.8  
 While Rabeprazole has been extensively studied in adults, these are the first studies 
published investigating the use of Rabeprazole in children ages 1-16 years old.1,2,3 Prior to these 
studies, other PPI’s were proven effective in this patient population, and therefore it was not 
ethical to include a placebo arm to assess the spontaneous response rate. 1,2,3 While this was a 
major limitation to these studies the association between an improved endoscopic score and 
improved clinical symptom score suggest that a placebo effect was not a major determining 
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factor in the outcomes.1,2,3 No deaths were reported during any of these studies, and “no dose-
response relation was observed with respect to TEAE’s”.1,2,3 Overall the number and the rate of 
TEAE’s commonly associated with Rabeprazole treatment were similar across all of the dose 
groups. 1,2,3  
CONCLUSION 
 This review and the chosen studies showed that Rabeprazole is a safe treatment for 
GERD in children 1-16 years of age. No serious or life-threatening adverse events were reported 
related to the use of Rabeprazole during these studies, and patient’s quality of life was 
improved. Further studies should be double-blinded studies and would be more beneficial if 
included a larger sample size. In the future, the development of a concrete scale for assessing 
the TEAE’s involved with the use of PPI’s would be beneficial. Also, future research should 
longer treatment durations to more definitively evaluate the benefits versus the risks of 
treating GERD with Rabeprazole in this younger population.  
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